Clinical Trials Browser

Phase 1/2 × Blast Crisis × Sorafenib × Clear all

NCT01445080 2021-02-02

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile